Proposed Substances To Be Evaluated for Toxicological Profile Development, 32039-32040 [2020-11423]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 103 / Thursday, May 28, 2020 / Notices
(Authority: Pub. L. 92–463, § 1, Oct. 6, 1972,
86 Stat. 770)
Dated: May 21, 2020.
Mary Ross,
Director, Office of Science Advisor, Policy,
and Engagement.
[FR Doc. 2020–11397 Filed 5–27–20; 8:45 am]
BILLING CODE 6560–50–P
Board of Governors of the Federal Reserve
System, May 22, 2020.
Yao-Chin Chao,
Assistant Secretary of the Board.
FEDERAL RESERVE SYSTEM
jbell on DSKJLSW7X2PROD with NOTICES
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
[FR Doc. 2020–11481 Filed 5–27–20; 8:45 am]
BILLING CODE P
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The applications listed below, as well
as other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank indicated. The
applications will also be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than June 11, 2020.
A. Federal Reserve Bank of
Minneapolis (Chris P. Wangen,
Assistant Vice President), 90 Hennepin
Avenue, Minneapolis, Minnesota
55480–0291:
1. The Bank Holding Company Stock
Trust Agreement of Steven R. Krause
and Rebecca R. Krause, Steven R.
Krause and Rebecca R. Krause as cotrustees, and Andrew Krause, all of
Winnebago, Minnesota; Erin Church,
Canistota, South Dakota; and Emily
Sebesta, Willmar, Minnesota; as
members of the Krause Family
Shareholder Group acting in concert to
retain voting shares of Krause Financial,
Inc., and thereby indirectly retain voting
shares of First Financial Bank in
Winnebago, both of Winnebago,
Minnesota.
B. Federal Reserve Bank of San
Francisco (Sebastian Astrada, Director,
Applications) 101 Market Street, San
Francisco, California 94105–1579:
VerDate Sep<11>2014
16:32 May 27, 2020
Jkt 250001
1. Megan F. Clubb and Clifford ‘‘Kip’’
W. Kontos, both of Walla Walla,
Washington, and Charles H. Eglin,
Yakima, Washington; as a group acting
in concert to acquire voting shares of
Baker Boyer Bancorp and thereby
indirectly acquire Baker Boyer National
Bank, both of Walla Walla, Washington.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[Docket No. ATSDR–2020–0002]
Proposed Substances To Be Evaluated
for Toxicological Profile Development
Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (HHS).
ACTION: Request for comments on
proposed substances to be evaluated for
Toxicological Profile development.
AGENCY:
The Agency for Toxic
Substances and Disease Registry
(ATSDR) within the Department of
Health and Human Services is initiating
the development of another set of
Toxicological Profiles. This notice
solicits public nominations of
substances for ATSDR to evaluate for
Toxicological Profile development.
ATSDR will consider nominations from
the Substance Priority List (available at
https://www.atsdr.cdc.gov/SPL/).
ATSDR also accepts nominations for
non-Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA) substances that
may have public health implications, on
the basis of ATSDR’s authority to
prepare Toxicological Profiles for
substances not found at sites on the
CERCLA National Priorities List. For
more information on the CERCLA
National Priorities List, visit https://
www.epa.gov/superfund/
superfundnational-priorities-list-npl.
The agency will do so in order to
establish and maintain an inventory of
literature, research, and studies on the
health effects of toxic substances, to
respond to requests for consultation,
and to support the site-specific response
actions conducted by ATSDR, as
otherwise necessary.
SUMMARY:
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
32039
Nominations from the Substance
Priority List and/or additional
substances must be received by June 29,
2020.
DATES:
You may submit
nominations, identified by Docket No.
ATSDR–2020–0002, by any of the
following methods:
• Internet: Access the Federal
eRulemaking portal at
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Division of Toxicology and
Human Health Sciences, Agency for
Toxic Substances and Disease Registry,
1600 Clifton Rd. NE, Mail Stop S102–1,
Atlanta, GA, 30329–4027. Attn: Docket
No. ATSDR–2020–0002.
Instructions: All submissions must
include the agency name and docket
number for this notice. All relevant
comments will be posted without
change. This means that no confidential
business information or other
confidential information should be
submitted in response to this notice.
Refer to the section Submission of
Nominations (below) for the specific
information required.
ADDRESSES:
For
further information, please contact
Susan Ingber, Agency for Toxic
Substances and Disease Registry,
Division of Toxicology and Human
Health Sciences, 1600 Clifton Rd. NE,
Mail Stop S102–1, Atlanta, GA, 30329–
4027, Email: ATSDRToxProfileFRNs@
cdc.gov; Phone: 1–800–232–4636.
FOR FURTHER INFORMATION CONTACT:
The
Superfund Amendments and
Reauthorization Act of 1986 (SARA) [42
U.S.C. 9601 et seq.] amended the
Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA or Superfund) [42
U.S.C. 9601 et seq.] by establishing
certain requirements for ATSDR and the
U.S. Environmental Protection Agency
(EPA) with regard to hazardous
substances most commonly found at
facilities on the CERCLA National
Priorities List (NPL) (for more
information, visit https://www.epa.gov/
superfund/superfund-nationalprioritieslist-npl). Among these statutory
requirements is a mandate for the
Administrator of ATSDR to prepare
Toxicological Profiles for each
substance included on the Priority List
of Hazardous Substances (also known as
the Substance Priority list (SPL)). This
list identifies 275 hazardous substances
found at NPL sites that ATSDR and EPA
have determined pose the most
significant current potential threat to
human health.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\28MYN1.SGM
28MYN1
32040
Federal Register / Vol. 85, No. 103 / Thursday, May 28, 2020 / Notices
Substances To Be Evaluated for
Toxicological Profile Development
Each year, ATSDR develops a list of
substances to be considered for
Toxicological Profile development. The
nomination process includes
consideration of all substances on
ATSDR’s SPL, as well as other
substances nominated by the public. For
more information on ATSDR’s SPL, visit
https://www.atsdr.cdc.gov/SPL/.
Submission of nominations for
Toxicological Profile development:
Today’s notice invites voluntary public
nominations for substances included on
the SPL and for substances not listed on
the SPL. When nominating a non-SPL
substance, please include the rationale
for the nomination. ATSDR will
evaluate data and information
associated with nominated substances
and will determine the final list of
substances to be chosen for
Toxicological Profile development.
Substances will be chosen according to
ATSDR’s specific guidelines for
selection. These guidelines can be found
in the Selection Criteria, which may be
accessed at www.atsdr.cdc.gov/
toxprofiles/guidance/ATSDR_TP_
Selection%20Criteria.pdf.
Pamela I. Protzel Berman,
Director, Office of Policy, Planning and
Partnerships, Agency for Toxic Substances
and Disease Registry.
[FR Doc. 2020–11423 Filed 5–27–20; 8:45 am]
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–D–1398]
Mitigation Strategies to Protect Food
Against Intentional Adulteration; Draft
Guidance for Industry; Extension of
the Comment Period
AGENCY:
Food and Drug Administration,
HHS.
Notice of availability; extension
of comment period
ACTION:
The Food and Drug
Administration (FDA, we, or the
Agency) is extending the comment
period for the notice of availability that
appeared in the Federal Register of
February 14, 2020, entitled ‘‘Mitigation
Strategies to Protect Food Against
Intentional Adulteration; Draft
Guidance for Industry.’’ This
supplemental draft guidance document,
when finalized, will help food facilities
that manufacture, process, pack, or hold
food, and that are required to register
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:32 May 27, 2020
Jkt 250001
to Protect Food Against Intentional
Adulteration: Supplemental Draft
Guidance for Industry.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
Electronic Submissions
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
Submit electronic comments in the
CONFIDENTIAL INFORMATION.’’ The
following way:
• Federal eRulemaking Portal: https:// Agency will review this copy, including
the claimed confidential information, in
www.regulations.gov. Follow the
its consideration of comments. The
instructions for submitting comments.
second copy, which will have the
Comments submitted electronically,
claimed confidential information
including attachments, to https://
redacted/blacked out, will be available
www.regulations.gov will be posted to
for public viewing and posted on
the docket unchanged. Because your
https://www.regulations.gov. Submit
comment will be made public, you are
solely responsible for ensuring that your both copies to the Dockets Management
Staff. If you do not wish your name and
comment does not include any
contact information to be made publicly
confidential information that you or a
available, you can provide this
third party may not wish to be posted,
information on the cover sheet and not
such as medical information, your or
anyone else’s Social Security number, or in the body of your comments and you
confidential business information, such must identify this information as
‘‘confidential.’’ Any information marked
as a manufacturing process. Please note
as ‘‘confidential’’ will not be disclosed
that if you include your name, contact
except in accordance with 21 CFR 10.20
information, or other information that
and other applicable disclosure law. For
identifies you in the body of your
more information about FDA’s posting
comments, that information will be
of comments to public dockets, see 80
posted on https://www.regulations.gov.
FR 56469, September 18, 2015, or access
• If you want to submit a comment
the information at: https://
with confidential information that you
www.govinfo.gov/content/pkg/FR-2015do not wish to be made available to the
09-18/pdf/2015-23389.pdf.
public, submit the comment as a
Docket: For access to the docket to
written/paper submission and in the
read background documents or the
manner detailed (see ‘‘Written/Paper
electronic and written/paper comments
Submissions’’ and ‘‘Instructions’’).
received, go to https://
Written/Paper Submissions
www.regulations.gov and insert the
docket number, found in brackets in the
Submit written/paper submissions as
heading of this document, into the
follows:
‘‘Search’’ box and follow the prompts
• Mail/Hand Delivery/Courier (for
and/or go to the Dockets Management
written/paper submissions): Dockets
Management Staff (HFA–305), Food and Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
Drug Administration, 5630 Fishers
You may submit comments on any
Lane, Rm. 1061, Rockville, MD 20852.
guidance at any time (see 21 CFR
• For written/paper comments
10.115(g)(5)).
submitted to the Dockets Management
Submit written requests for single
Staff, FDA will post your comment, as
copies of the guidance to the Center for
well as any attachments, except for
Food Safety and Applied Nutrition,
information submitted, marked and
Food and Drug Administration, 5001
identified, as confidential, if submitted
Campus Dr., College Park, MD 20740.
as detailed in ‘‘Instructions.’’
Instructions: All submissions received Send two self-addressed adhesive labels
to assist that office in processing your
must include the Docket No. FDA–
requests. See the SUPPLEMENTARY
2018–D–1398 for ‘‘Mitigation Strategies
under the Federal Food, Drug, and
Cosmetic Act comply with the
requirements of our regulation entitled
‘‘Mitigation Strategies to Protect Food
Against Intentional Adulteration.’’ FDA
is taking this action in response to a
request for an extension to allow
interested persons additional time to
submit comments.
DATES: FDA is extending the comment
period on the notice of availability
published February 14, 2020 (85 FR
8599). Submit either electronic or
written comments on the supplemental
draft guidance by August 14, 2020.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
E:\FR\FM\28MYN1.SGM
28MYN1
]]>Agencies
[Federal Register Volume 85, Number 103 (Thursday, May 28, 2020)]
[Notices]
[Pages 32039-32040]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-11423]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Toxic Substances and Disease Registry
[Docket No. ATSDR-2020-0002]
Proposed Substances To Be Evaluated for Toxicological Profile
Development
AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR),
Department of Health and Human Services (HHS).
ACTION: Request for comments on proposed substances to be evaluated for
Toxicological Profile development.
-----------------------------------------------------------------------
SUMMARY: The Agency for Toxic Substances and Disease Registry (ATSDR)
within the Department of Health and Human Services is initiating the
development of another set of Toxicological Profiles. This notice
solicits public nominations of substances for ATSDR to evaluate for
Toxicological Profile development. ATSDR will consider nominations from
the Substance Priority List (available at https://www.atsdr.cdc.gov/SPL/). ATSDR also accepts nominations for non-Comprehensive
Environmental Response, Compensation, and Liability Act of 1980
(CERCLA) substances that may have public health implications, on the
basis of ATSDR's authority to prepare Toxicological Profiles for
substances not found at sites on the CERCLA National Priorities List.
For more information on the CERCLA National Priorities List, visit
https://www.epa.gov/superfund/superfundnational-priorities-list-npl.
The agency will do so in order to establish and maintain an inventory
of literature, research, and studies on the health effects of toxic
substances, to respond to requests for consultation, and to support the
site-specific response actions conducted by ATSDR, as otherwise
necessary.
DATES: Nominations from the Substance Priority List and/or additional
substances must be received by June 29, 2020.
ADDRESSES: You may submit nominations, identified by Docket No. ATSDR-
2020-0002, by any of the following methods:
Internet: Access the Federal eRulemaking portal at
www.regulations.gov. Follow the instructions for submitting comments.
Mail: Division of Toxicology and Human Health Sciences,
Agency for Toxic Substances and Disease Registry, 1600 Clifton Rd. NE,
Mail Stop S102-1, Atlanta, GA, 30329-4027. Attn: Docket No. ATSDR-2020-
0002.
Instructions: All submissions must include the agency name and
docket number for this notice. All relevant comments will be posted
without change. This means that no confidential business information or
other confidential information should be submitted in response to this
notice. Refer to the section Submission of Nominations (below) for the
specific information required.
FOR FURTHER INFORMATION CONTACT: For further information, please
contact Susan Ingber, Agency for Toxic Substances and Disease Registry,
Division of Toxicology and Human Health Sciences, 1600 Clifton Rd. NE,
Mail Stop S102-1, Atlanta, GA, 30329-4027, Email:
[email protected]; Phone: 1-800-232-4636.
SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization
Act of 1986 (SARA) [42 U.S.C. 9601 et seq.] amended the Comprehensive
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA
or Superfund) [42 U.S.C. 9601 et seq.] by establishing certain
requirements for ATSDR and the U.S. Environmental Protection Agency
(EPA) with regard to hazardous substances most commonly found at
facilities on the CERCLA National Priorities List (NPL) (for more
information, visit https://www.epa.gov/superfund/superfund-nationalpriorities-list-npl). Among these statutory requirements is a
mandate for the Administrator of ATSDR to prepare Toxicological
Profiles for each substance included on the Priority List of Hazardous
Substances (also known as the Substance Priority list (SPL)). This list
identifies 275 hazardous substances found at NPL sites that ATSDR and
EPA have determined pose the most significant current potential threat
to human health.
[[Page 32040]]
Substances To Be Evaluated for Toxicological Profile Development
Each year, ATSDR develops a list of substances to be considered for
Toxicological Profile development. The nomination process includes
consideration of all substances on ATSDR's SPL, as well as other
substances nominated by the public. For more information on ATSDR's
SPL, visit https://www.atsdr.cdc.gov/SPL/.
Submission of nominations for Toxicological Profile development:
Today's notice invites voluntary public nominations for substances
included on the SPL and for substances not listed on the SPL. When
nominating a non-SPL substance, please include the rationale for the
nomination. ATSDR will evaluate data and information associated with
nominated substances and will determine the final list of substances to
be chosen for Toxicological Profile development. Substances will be
chosen according to ATSDR's specific guidelines for selection. These
guidelines can be found in the Selection Criteria, which may be
accessed at www.atsdr.cdc.gov/toxprofiles/guidance/ATSDR_TP_Selection%20Criteria.pdf.
Pamela I. Protzel Berman,
Director, Office of Policy, Planning and Partnerships, Agency for Toxic
Substances and Disease Registry.
[FR Doc. 2020-11423 Filed 5-27-20; 8:45 am]
BILLING CODE 4163-70-P
